Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer. [electronic resource]
Producer: 20050118Description: S74-80 p. digitalISSN:- 1533-0028
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bevacizumab
- Clinical Trials, Phase III as Topic
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Male
- Maximum Tolerated Dose
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Neovascularization, Pathologic -- prevention & control
- Organoplatinum Compounds -- administration & dosage
- Phthalazines -- administration & dosage
- Pyridines -- administration & dosage
- Risk Assessment
- Survival Analysis
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.